Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
James Inglese · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · 2024 · $766,601 — This project includes the development of biochemical and target-focused assays based on specific protein or nucleic acid targets implicated in disease. The assay designs are considered in the context of analysis and progression strategies for evaluation of a wide range of compound classes using hi…
Ruili Huang · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · 2024 · $847,482 — The Tox21 Programs federal partners include the Environmental Protection Agency (EPA), the Food and Drug Administration (FDA) and NIH, with leadership from NCATS and the National Toxicology Program (NTP) at the National Institute of Environmental Health Sciences (NIEHS). These agencies work together…
Daniel Kastner · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · 2024 · $1,583,024 — African American Scleroderma During the current reporting period several collaborative projects have come close to fruition, and I anticipate that Dr. Gourh will have several manuscripts ready for submission within the next few months. 1) The role of NOTCH4 in the vasculopathy of SSc: Using a gene…
D. Rebecca Prevots · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $80,385 — Background Prior research has shown variability in household secondary attack rates (SAR) and transmission risks of SARS-CoV-2, which remains poorly understood. To address these questions, we conducted a household serologic study nested within a larger prospective cohort study of SARS-CoV-2 in Cost…
Matthew Wheeler · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · 2024 · $101,426 — With the increasing complexity of large datasets, the development of novel statistical techniques that can create informative analyses, which allow scientists and decision makers, to leverage the richness of the data source is needed. This research seeks to develop methodologies that extract meanin…
FRED R HIRSCH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $119,921 — ADMINISTRATIVE CORE: ABSTRACT Our inter-institutional U54 Serological Sciences Center of Excellence (“U54”) Administrative Core provides scientific and administrative oversight for all of the U54’s Projects and Cores. It also provides the main interface with patient advocates, NCI program staff, ex…
Rachel M Olson · UNIVERSITY OF MISSOURI-COLUMBIA · 2024 · $921,558 — Project Summary Core 3: Biocontainment Research Support Services Core The objective of the Biocontainment Research Support Services Core (BRSSC, Core 3) is to provide sustainable research resources that facilitate the pre-clinical development of medical countermeasures against emerging and re-emergi…
Colin S. Duckett · DUKE UNIVERSITY · 2024 · $957,509 — ABSTRACT- Biocontainment Research Support Services Core (Core 3) The central mission of the Duke RBL is to support the basic and translational research necessary to develop drugs, diagnostics, and vaccines for emerging/reemerging infections and biodefense. Support through this award will allow us to…
Farhang Alem · GEORGE MASON UNIVERSITY · 2024 · $919,306 — BIOCONTAINMENT RESEACRCH SERVICES: ABSTRACT Each of the twelve NIAID funded Regional Biocontainment Laboratories (RBLs) have distinguishing and complementary research capabilities to advance infectious disease and biodefense research. George Mason University’s (GMU)’s RBL, also known as the Biomedic…
JEFFREY Joseph ADAMOVICZ · UNIVERSITY OF MISSOURI-COLUMBIA · 2024 · $718,778 — Project Summary Core 2: Biosafety Level 3 Practices The Biosafety Level 3 Practices Core (BPC) at the Laboratory of Infectious Disease Research (LIDR) includes three major components: Biosafety and emergency planning, user training and competency oversight, and select agent program management. The …
CALVIN J KUO · STANFORD UNIVERSITY · 2024 · $452,832 — PROJECT SUMMARY (Core B: Organoid Core) Infectious disease research is substantially hampered by lack of experimental models necessary to study interactions between pathogens and target tissues; a glaring deficiency amplified by the recent COVID-19 pandemic. The recent advent of 3D organoid methods …
Ighovwerha Ofotokun · EMORY UNIVERSITY · 2024 · $524,909 — Modified Project Summary/Abstract Section The Clinical Research Core (CRC) (Core D) provides services to support researchers conducting human subjects research studies investigating the pathogenesis of HIV disease, treatment and prevention of HIV, strategies to eliminate HIV from those who are inf…
Gehan Devendra · UNIVERSITY OF HAWAII AT MANOA · 2024 · $348,102 — PROJECT SUMMARY/ABSTRACT Nearly one third of individuals who recover from acute COVID-19 will have chronic symptoms, so called ‘Post- Acute Sequelae of SARS-CoV-2’ infection (PASC). Among individuals with PASC, pulmonary complications such as persistent dyspnea and chronic cough are common. Although…
Alessandro Sette · LA JOLLA INSTITUTE FOR IMMUNOLOGY · 2024 · $212,201 — CORE B, CLINICAL CORE SUMMARY The success of the entire program is contingent upon successful accrual of human samples. The purpose of Core B (Clinical Core) is to provide a centralized resource for the accrual of human lymph node (LN), head and neck, nasopharyngeal swab (NP), peripheral blood monon…
ROBIN L AUPPERLE · LAUREATE INSTITUTE FOR BRAIN RESEARCH · 2024 · $328,850 — PROJECT SUMMARY: Recruitment and Assessment Core Psychiatric research relies on the use of validated and reliable self-report, interview-based, and behavioral assessments to diagnose DSM-5 psychiatric disorders, estimate level of severity of mental health symptoms, and to delineate transdiagnostic c…
Kyeong-Ok Chang · KANSAS STATE UNIVERSITY · 2024 · $773,323 — PROJECT SUMMARY Middle East respiratory syndrome coronavirus (MERS-CoV) emerged suddenly in 2012 as the cause of severe respiratory illness in humans. Despite the high mortality rate (~ 40%) and the significant potential for a public health emergency, there are no FDA-approved vaccines or antiviral…
Hardy Kornfeld · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2024 · $7,857,615 — Program Summary/Abstract The University of Massachusetts Chan Medical School (UMass Chan) seeks NIH C06 funding to renovate existing space in the medical school (S) building to construct an in vitro Biosafety Level 3 (BSL-3) laboratory for viral pathogens. As an internationally recognized leader in …
Jessica Chuang Seeliger · STATE UNIVERSITY NEW YORK STONY BROOK · 2024 · $239,250 — SUMMARY The search for more effective treatment and prevention of tuberculosis has motivated the identification genes that are essential for the growth and survival of the causative agent, Mycobacterium tuberculosis (Mtb). These genes are potential new targets for developing and attenuated live vac…
Shannon Jones McCall · DUKE UNIVERSITY · 2024 · $719,670 — PROJECT ABSTRACT High-quality biospecimens are critical to cancer research. The CHTN Southern Division leverages the CAP- accredited biorepository broad-consent framework and faculty/staff expertise of the Duke BioRepository & Precision Pathology Center (BRPC) to provide high-quality biospecimens to…
Alexander Viloria Winnett · CALIFORNIA INSTITUTE OF TECHNOLOGY · 2024 · $22,888 — PROJECT SUMMARY Morbidity and mortality in COVID-19 is the result of an exaggerated inflammatory response causing severe tissue and organ damage. However, the biological mechanism for why some individuals progress from initially stable to ultimately critical condition has not been fully elucidated. …